公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2014 | Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling | Chen W.-J.; CHAO-CHI HO ; YIH-LEONG CHANG ; Chen H.-Y.; Lin C.-A.; THAI-YEN LING ; SUNG-LIANG YU ; Yuan S.-S.; Louisa Chen Y.-J.; Lin C.-Y.; SZU-HUA PAN ; HAN-YI E. CHOU ; Chang G.-C.; Chu W.-C.; Lee Y.-M.; Lee J.-Y.; Lee P.-J.; Li K.-C.; HUEI-WEN CHEN ; PAN-CHYR YANG | Nature Communications | 302 | 278 | |
2018 | Characteristics and Predictive Value of PD-L1 Status in Real-World NonSmall Cell Lung Cancer Patients | Tseng J.-S.; Yang T.-Y.; Wu C.-Y.; Ku W.-H.; Chen K.-C.; Hsu K.-H.; Huang Y.-H.; KANG-YI SU ; SUNG-LIANG YU ; Chang G.-C. | Journal of Immunotherapy | 28 | 25 | |
2016 | Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status | Hsu C.-H.; Tseng C.-H.; CHUN-JU CHIANG ; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.-H.; Chiu C.-H.; Huang M.-S.; CHONG-JEN YU ; Tsai Y.-H.; JIN-SHING CHEN ; Tsai C.-M.; Chou T.-Y.; Lin K.-C.; Tsai M.-H.; WEN-CHUNG LEE ; Ku H.-Y.; Liu T.-W.; Yang T.-Y.; Chang G.-C. | Oncotarget | 38 | 30 | |
2009 | Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma | Chao Y.-C.; SZU-HUA PAN ; Yang S.-C.; SUNG-LIANG YU ; Che T.-F.; CHUNG-WU LIN ; Tsai M.-S.; Chang G.-C.; Wu C.-H.; Wu Y.-Y.; Lee Y.-C.; Hong T.-M.; PAN-CHYR YANG | American Journal of Respiratory and Critical Care Medicine | 152 | 142 | |
2011 | Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach | Salto-Tellez M.; Tsao M.-S.; JIN-YUAN SHIH ; Thongprasert S.; Lu S.; Chang G.-C.; Au J.S.-K.; Chou T.-Y.; Lee J.-S.; Shi Y.-K.; Radzi A.; Kang J.-H.; Kim S.-W.; Tan S.-Y.; CHIH-HSIN YANG | Journal of Thoracic Oncology | 35 | 36 | |
2011 | Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations | Yuan S.; SUNG-LIANG YU ; Chen H.-Y.; Hsu Y.-C.; KANG-YI SU ; HUEI-WEN CHEN ; Chen C.-Y.; CHONG-JEN YU ; JIN-YUAN SHIH ; YIH-LEONG CHANG ; Cheng C.-L.; Hsu C.-P.; Hsia J.-Y.; Lin C.-Y.; Wu G.; Liu C.-H.; Wang C.-D.; Yang K.-C.; Chen Y.-W.; Lai Y.-L.; Hsu C.-C.; Lin T.-C.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Chen J.J.W.; Chang G.-C.; Li K.-C.; PAN-CHYR YANG | Journal of Clinical Oncology | 28 | 26 | |
2011 | Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: The versatile adjuvant for gefitinib therapy | Lee J.-Y.; Lee Y.-M.; Chang G.-C.; SUNG-LIANG YU ; Hsieh W.-Y.; Chen J.J.W.; HUEI-WEN CHEN ; PAN-CHYR YANG | PLoS ONE | 111 | 86 | |
1998 | Diagonal recurrent neural network based FES system for the knee joint position control | JER-JUNN LUH ; Chang G.-C.; JIN-SHIN LAI ; Cheng C.-K.; Kuo T.-S.; Lee J.-F. | Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings | 1 | ||
2022 | Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial | Lu S.; Wang Q.; Zhang G.; Dong X.; Yang C.-T.; Song Y.; Chang G.-C.; Lu Y.; Pan H.; Chiu C.-H.; Wang Z.; Feng J.; Zhou J.; Xu X.; Guo R.; Chen J.; Yang H.; Chen Y.; Yu Z.; Shiah H.-S.; Wang C.-C.; Yang N.; Fang J.; Wang P.; Wang K.; Hu Y.; He J.; Wang Z.; Shi J.; Chen S.; Wu Q.; Sun C.; Li C.; Wei H.; Cheng Y.; Su W.-C.; Hsia T.-C.; Cui J.; Sun Y.; Ou S.-H.I.; Zhu V.W.; CHIH-HSIN YANG | Journal of Thoracic Oncology | 67 | 51 | |
2013 | EGFR exon 19 in-frame deletion and polymorphisms of DNA repair genes in never-smoking female lung adenocarcinoma patients | Yang S.-Y.; Yang T.-Y.; Li Y.-J.; Chen K.-C.; Liao K.-M.; Hsu K.-H.; Tsai C.-R.; Chen C.-Y.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Tsai Y.-H.; KUAN-YU CHEN ; Huang M.-S.; Su W.-C.; Chen Y.-M.; Hsiung C.A.; Shen C.-Y.; Chang G.-C.; PAN-CHYR YANG ; Chen C.-J. | International Journal of Cancer | 11 | 10 | |
2011 | EGFR L858R mutation and polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients | Yang S.-Y.; Yang T.-Y.; Chen K.-C.; Li Y.-J.; Hsu K.-H.; Tsai C.-R.; Chen C.-Y.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Tsai Y.-H.; KUAN-YU CHEN ; Huang M.-S.; Su W.-C.; Chen Y.-M.; Hsiung C.A.; Shen C.-Y.; Chang G.-C.; PAN-CHYR YANG ; Chen C.-J. | Clinical Cancer Research | 27 | 25 | |
2015 | EGFR mutation and lobar location of lung adenocarcinoma | Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; CHAO-CHI HO ; Hsia T.-C.; KANG-YI SU ; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; KUAN-YU CHEN ; WEI-YU LIAO ; JIN-YUAN SHIH ; SUNG-LIANG YU ; CHONG-JEN YU ; PAN-CHYR YANG ; Yang T.-Y.; Chang G.-C. | Carcinogenesis | 11 | 12 | |
2013 | EGFR polymorphisms, hormone replacement therapy and lung adenocarcinoma risk: analysis from a genome-wide association study in never-smoking women | KUAN-YU CHEN ; Hsiao C.-F.; Chang G.-C.; Tsai Y.-H.; Su W.-C.; Chen Y.-M.; Huang M.-S.; Hsiung C.A.; Chen C.-J.; PAN-CHYR YANG | Carcinogenesis | 17 | 14 | |
2016 | EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma | Chen H.-Y.; Liu C.-H.; Chang Y.-H.; SUNG-LIANG YU ; Ho B.C.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Chang C.-S.; Li Y.-C.; Li K.-C.; Chang G.-C.; PAN-CHYR YANG | Oncotarget | 14 | 16 | |
2016 | The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: Focus on rebiopsy timing and long-term existence of T790M | Tseng J.-S.; KANG-YI SU ; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Chen H.-Y.; Tsai C.-R.; SUNG-LIANG YU ; Chang G.-C. | Oncotarget | 24 | 23 | |
2011 | Epidermal growth factor receptor mutation status in stage i lung adenocarcinoma with different image patterns | Hsu K.-H.; Chen K.-C. ; Yang T.-Y.; Yeh Y.-C.; Chou T.-Y.; Chen H.-Y.; Tsai C.-R.; Chen C.-Y.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Tsai Y.-H.; KUAN-YU CHEN ; Huang M.-S.; Su W.-C.; Chen Y.-M.; Hsiung C.A.; Chang G.-C.; Chen C.-J.; PAN-CHYR YANG | Journal of Thoracic Oncology | 47 | 42 | |
2015 | Estrogen receptor gene polymorphisms and lung adenocarcinoma risk in never-smoking women | KUAN-YU CHEN ; Hsiao C.-F.; Chang G.-C.; Tsai Y.-H.; Su W.-C.; Chen Y.-M.; Huang M.-S.; Tsai F.-Y.; Jiang S.-S.; Chang I.-S.; Chen C.-Y.; Hsiung C.A.; Chen C.-J.; PAN-CHYR YANG | Journal of Thoracic Oncology | 21 | 14 | |
2020 | Exercise experiences in patients with metastatic lung cancer: A qualitative approach | Chang P.-H.; Lin C.-R.; YUN-HSIANG LEE ; Liu Y.-L.; Chang G.-C.; Hoogland A.I.; YEUR-HUR LAI | PLoS ONE | 6 | 3 | |
2021 | Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations | Chang G.-C.; Lam D.C.-L.; Tsai C.-M.; Chen Y.-M.; JIN-YUAN SHIH ; Aggarwal S.; Wang S.; Kim S.-W.; Kim Y.-C.; Wahid I.; Li R.; Lim D.W.-T.; Sriuranpong V.; Chan R.T.-T.; Lorence R.M.; Carriere P.; Raabe C.; Cseh A.; Park K. | International Journal of Clinical Oncology | 2 | 2 | |
2018 | FAM198B is associated with prolonged survival and inhibits metastasis in lung adenocarcinoma via blockage of ERK-Mediated MMP-1 expression | Hsu C.-Y.; Chang G.-C.; Chen Y.-J.; Hsu Y.-C.; Hsiao Y.-J.; KANG-YI SU ; Chen H.-Y.; Lin C.-Y.; JIN-SHING CHEN ; Chen Y.-J.; Hong Q.-S.; Ku W.-H.; Wu C.-Y.; Ho B.-C.; Chiang C.-C.; PAN-CHYR YANG ; SUNG-LIANG YU | Clinical Cancer Research | 19 | 20 |